KLAS Contact
Contact KLAS
Contact KLAS
2024 BEST IN KLAS
Preferences
Related Series
2020
2016
2014
2013
2012
2011
2010
2008
Related Segments
Oncology 2023
Market Dynamics Shifting for Medical and Radiation Oncology Information Systems
Author
Monique Rasband
Author
Sidney Tate
Author
Spencer Corbett
The market for both medical and radiation oncology EMRs is shifting. For medical oncology, many previously independent oncology practices and cancer centers have been consolidated into larger health systems, leading to the adoption of medical oncology modules from acute care EMR vendors—a trend that is set to continue. Additionally, customer satisfaction in the radiation oncology market has shifted in recent years as the two primary vendors have competed for each other’s customers. Leveraging the perspectives of 158 organizations, this report explores the performance of medical and radiation oncology EMR vendors to see which are meeting customer needs and which are falling behind.
If you don't have a login, getting started is easy.
Key Findings:
- Amid Market Consolidation, Epic Works to Build More Robust Oncology Functionality, Oracle Health (Cerner) Slow with Oncology Development
- For Medical Oncology in Community Centers, Ontada (McKesson) and Flatiron Health Maintain Strong Performance with Intuitive Products and Responsive Support
- For Medical Oncology, Elekta Customers See Strengthened Engagement; Varian (Limited Data) Customers Report Less Focus
- For Radiation Oncology, Varian Customers See Overall Improvement; Elekta Customers Report Little Progress
Writer
Carlisa Cramer
Designer
Bronson Allgood
Project Manager
Ally Dove
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.